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The cytokine erythropoietin (EPO) stimulates proliferation and differentiation of erythroid progenitor cells. Moreover, EPO has
neuroprotective, anti-inflammatory, and antioxidative effects, but the use of EPO as a neuroprotective agent is hampered by its
erythropoietic activity. We have recently designed the synthetic, dendrimeric peptide, Epobis, derived from the sequence of human
EPO. This peptide binds the EPO receptor and promotes neuritogenesis and neuronal cell survival. Here we demonstrate that
Epobis in vitro promotes neuritogenesis in primary motoneurons and has anti-inflammatory effects as demonstrated by its ability
to decrease TNF release from activated AMJ2-C8macrophages and rat primary microglia. When administered systemically Epobis
is detectable in both plasma and cerebrospinal fluid, demonstrating that the peptide crosses the blood-brain barrier. Importantly,
Epobis is not erythropoietic, but systemic administration of Epobis in rats delays the clinical signs of experimental autoimmune
encephalomyelitis, an animal model of multiple sclerosis, and the peptide has long-term, but not short-term, effects on working
memory, detected as an improved social memory 3 days after administration. These data reveal Epobis to be a nonerythropoietic
and neuroprotective EPO receptor agonist with anti-inflammatory and memory enhancing properties.
1. Background
Erythropoietin (EPO) is a secreted glycoprotein mainly
produced in the kidney and liver. It serves as a cytokine
strongly upregulated by hypoxia and stimulates erythro-
poiesis by binding to EPO receptors localized on erythroid
progenitor cells. The erythropoietic property of EPO is
utilized clinically for the treatment of, for example, anemia
caused by renal failure or chemotherapeutic cancer therapy
(reviewed by [1]). However, EPO and the EPO receptor also
have additional functions. They are widely expressed in the
brain, where EPO has anti-inflammatory, antiapoptotic, and
neuroprotective effects, protects against oxidative stress and
excitotoxicity, and stimulates angiogenesis and neurogenesis
(reviewed by [2, 3]). Consequently, EPO has been evaluated
for the treatment of several diseases in the nervous system
including neurodegenerative diseases like Parkinson’s disease
[4] and multiple sclerosis [5, 6] and various types of ischemia
including carbon monoxide poisoning [7, 8], subarachnoid
hemorrhage [9], and Friedreich’s ataxia [10]. Moreover, EPO
has beneficial effects on memory and mood of animals
and humans with depression-like symptoms [11]. Animal
studies using EPO or EPO derivatives have demonstrated
an improved memory and a reduced endothelial and neu-
ronal degeneration in models of Alzheimer’s disease [12–
14], a protection against experimental cerebral malaria and
pneumococcal meningitis [15, 16], downregulation of proin-
flammatory cytokines and upregulation of anti-inflammatory
cytokines in a model of amyotrophic lateral sclerosis [17],
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a reduction of progressive retinal degeneration [18], and neu-
roprotective effects in relation to status epilepticus [19] and
cervical subacute spinal cord compression [20]. Importantly,
most of these beneficial effects of EPOare believed to be unre-
lated to the erythropoietic effects of EPO but not necessarily
unrelated to signaling through the EPO receptor [1–3].
There are two problems associated with the systemic
administration of EPO for the treatment of diseases in the
nervous system: one problem is the poor transport of the
protein across the blood-brain barrier (BBB) [7]; another
problem is that the erythropoietic activity of EPO can cause
polycythemia and thereby increase the risk of thrombosis
or other adverse effects [9]. To circumvent these problems
attempts have beenmade to design EPOderivatives thatmore
readily cross the BBB and/or have reduced erythropoietic
activities. One EPO derivative able to cross the BBB has
been formed by generating a chimeric protein consisting
of EPO fused to an antibody against the transferrin recep-
tor [21]. Nonerythropoietic EPO derivatives include the
mutants EpoR76E and EpoS71E (see [22]), carbamylated EPO
(CEPO), EPO with low or no sialylation (neuro-EPO and
asialoEPO, resp.) [23], and the peptides pHBSP/ARA290 [24,
25] and Epotris [26].
Structurally, EPO consists of 4 𝛼-helices (A–D) linked by
loops. A single EPO molecule interacts with predimerized
EPO receptors via 2 separate binding sites: binding site 1,
which is located in helices A, B, and D and a part of the AB
loop, and binding site 2, located in helices A and C [27].
We have previously designed two synthetic, dendrimeric
peptides with sequences corresponding to the first and
the second EPO receptor binding site of human EPO,
respectively. The peptide derived from binding site 2 was
named Epotris and has previously been reported to promote
neuritogenesis and neuronal survival in vitro and in vivo
in a nonerythropoietic manner [26] and to attenuate status
epilepticus [28]. The peptide derived from binding site 1
(residues 36–53 in the structural model of the EPO:EPO
receptor-complex; PDB: 1EER [27]) was named Epobis, and
surface plasmon resonance analysis has revealed that this
peptide sequence specifically binds the EPO receptor with
apparent 𝐾D around 60 nM. Moreover, the peptide induces
neuritogenesis in primary cultures of cerebellar granule
neurons and hippocampal neurons in a dose-dependent
and EPO receptor-dependent manner. Epobis also protects
against neuronal cell death in vitro, and, like EPO, it promotes
activation of the transcription factor STAT5 [29].
Here, we present data suggesting that Epobis is a nonery-
thropoietic and neuroprotective EPO receptor agonist with
anti-inflammatory and memory enhancing properties.
2. Methods
2.1. Peptide. The Epobis peptide sequence, NENITVPDTKVN-
FYAWKR, corresponding to amino acids 63–80 of human
EPO (Uniprot P01588)was synthesized as a tetramer (Schafer-
N, Copenhagen, Denmark) as described previously [29].
2.2. Neurite Outgrowth from Primary Motoneurons. Primary
rat motoneurons were isolated as described previously [30].
Briefly, the ventral horns of the lumbar spinal cord were
dissected from Wistar rat embryos (E15). The dissociated
motoneurons were plated at a density of 7,000 cells per
well on laminin-coated (5𝜇g/mL; Sigma-Aldrich) 8-well
LabTek Permanox slides (NUNC, Denmark). Neurons were
stimulated with serially diluted Epobis peptide for 24 h, fixed
with 4% formalin, stained with polyclonal rabbit anti-rat
growth-associated protein-43 antibodies (1 : 1000; Millipore),
and analyzed by computer-assisted fluorescence microscopy
as described [29].
2.3. Macrophage Activation Assay. The macrophage activa-
tion assay is used to estimate tumor necrosis factor (TNF)
secretion from the macrophage cell line AMJ2-C8 (ATCC;
Boras, Sweden). Fibroblastoid mouse L929 cells (L-cells;
ECCC, Salisbury, UK) are sensitive to TNF upon exposure to
actinomycin D, and L-cell survival can therefore be utilized
as an indirect estimate of TNF concentrations [31]. The assay
was performed essentially as described previously [32, 33].
Briefly, AMJ2-C8 cells were plated in 6-well MultiDish plates
(Nunc, Denmark) and treated with 100𝜇M hydrocortisone
(Sigma-Aldrich, Brøndby, Denmark), 0.3 ng/mL (8.4 nM)
rhEPO (Calbiochem, Merck Millipore, Denmark), or Epobis
(0.9–8.1 𝜇M) for 24 h. They were then exposed to 10 ng/mL
interferon-𝛾 (IFN-𝛾) (R&D Systems, UK) for 24 h to induce
the production of TNF [34].
L-cells were seeded in 96-well Multiwell plates (2 ×
105 cells/mL, 100𝜇L/well; Nunc) and grown for 24 h. Then
conditioned medium from stimulated macrophages was col-
lected and added to the L-cells together with actinomycin D
(Sigma, Sigma-Aldrich). L-cell viability was assayed 24 h later
by the MTS assay (Promega, Madison, WI, USA) according
to the manufacture’s protocol. Cell viability was calculated as
follows:
cell viability (%) = (ODexperiment
ODcontrol
) × 100. (1)
Estimates of TNF concentrations in the supernatants from
AMJ2-C8 cells were based on standard dose-response curves
for L-cell viability made using recombinant mouse TNF
(R&D System, MN, USA).
2.4. Preparation of Rat Primary Microglia Cell. Mixed glial
cultures were prepared from 1-day-old to 2-day-oldWistar rat
pups as described previously [35]. Briefly, cortices were dis-
sected, roughly chopped, and incubated in prewarmed 0.5%
trypsin for 10min.ThenDulbecco’s modified Eagle’s medium
(DMEM) plus GlutaMAX (culture media; Gibco) containing
10% fetal calf serum, penicillin (100U/mL), and streptomycin
(100U/mL) was added and tissue was triturated.The suspen-
sion was centrifuged at 500×g for 10min, and the resulting
pellet was resuspended in culture media and plated in a
poly-L-lysine-coated T180 flask. The mixed glial culture was
grown for 2-3 weeks at 37∘C in a humidified 5% CO2 : 95%
air environment.Themediumwas changed first at day 2 after
culture preparation and then every 5-6 days. After 2-3 weeks,
loosely attachedmicroglia cells were shaken off (250 RPM, 4 h
at 37∘C); medium was collected and centrifuged for 10min
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(500×g at 4∘C). The resuspended microglia cells were plated
onto 24-well plates (2.5 × 105 cell/mL/well) and incubated for
1-2 days.The purities ofmicroglial cultures were confirmed in
a separate experiment by staining cells with a rabbit anti-Iba-
1 antibody (1 : 2000; Wako) and counterstaining with DAPI-
containingmountingmedia (Molecular Probes). Imageswere
recorded using a Zeiss Axiovert 100 microscope mounted
with an AxioCam MRm camera using the accompanying
ZEN 2012 software.
To induce TNF secretion, microglia cells were treated
with lipopolysaccharide (LPS; 100 ng/mL; Sigma) following
1 h pretreatment in the absence or presence of Epobis. Con-
ditioned media were collected 24 h later and released TNF
was determined using a rat TNF Ready-SET-Go! ELISA kit
according to the manufacturer’s instructions (eBioscience,
San Diego, USA).
2.5. In Vivo Experiments. All in vivo experiments were per-
formed according to European Union legislations and with
a license from the Danish Animal Experiments Inspectorate
(2008/561-1539).
2.5.1. Detection of Epobis in Plasma and Cerebrospinal Fluid.
Detection of biotinylated Epobis in plasma was performed
essentially as described previously [26]. Briefly, 10mg/kg
Epobis was injected subcutaneously (s.c.) in anaesthetized
200 g Wistar rats, and blood samples were collected from
the orbital plexus at selected time points. Cerebrospinal fluid
(CSF) was sampled from the cisterna magna as described
previously [36].
Subsequently the concentrations of peptide in serum
plasma and CSF were estimated using a competitive enzyme-
linked immunosorbent assay, where all samples were run in
duplicate [26, 36].
2.5.2.Hematopoiesis Assay. Estimates of hematopoietic activ-
ity of Epobis in female C57BL/6J mice were performed essen-
tially as described previously [26]. Briefly, Epobis (10mg/kg),
EPO (10mg/kg; Calbiochem), or vehicle (PBS) was injected
subcutaneously twice per week for 5 weeks. Blood samples
were collected from the orbital plexus once per week, and
hemoglobin levels and hematocrit values were determined as
described [26].
2.5.3. Experimental Autoimmune Encephalomyelitis (EAE).
Experimental autoimmune encephalomyelitis (EAE) was
induced as described previously [33]. Briefly, female Lewis
rats (200 g) received subcutaneous injections at both sides of
the base of the tail with 0.2mL of an emulsion containing
1 g/LGuinea pigmyelin basic protein and 1 g/LM. tuberculosis
in Freund’s complete adjuvant (all from Sigma-Aldrich). The
injections were performed under full inhalation anesthesia.
EAE was induced in 30 animals; 6 healthy, age-matched,
unimmunized rats were used as controls. Between day 0 and
day 21, the weight and clinical signs of EAE were recorded
daily for all animals. Clinical signs were scored as follows: 0,
no abnormality; 0.5, weak tail; 1, limp tail; 2, mild palsy of
one or both hind legs; 3, severe palsy of one or both hind legs;
4, complete paralysis of one or both hind legs; 5, paralysis of
one or both hind legs and beginning paralysis of front legs;
6, moribund. Animals with a clinical score ≥4 were sacrificed
immediately.
Starting at day 10 after induction of EAE, animals
were treated once/day for 5 consecutive days with Epobis
(10mg/kg, 1mL/kg, s.c.) or PBS (1.0mL/kg, s.c.). The control
group is identical to the control group of previously published
data [33] performed simultaneously with the Epobis study.
2.5.4. Social Recognition Test. The social recognition assay
evaluates short-term/working memory of adult rats, a type
of memory known to be impaired in old (>18 month) rats
[37] and in rats experiencing early stage AD [38]. Social
recognition in rats was evaluated essentially as described
previously [39]. First, a habituation session was carried out;
24 h later, Epobis (10mg/kg, 1mL/kg, s.c.) or PBS (1.0mL/kg,
s.c.) was administered, and 1 h later the test animals were
introduced to a new, juvenile male rat for 4min (initial trial).
After another 2.5 h the same juvenile rat was reintroduced, or
as a control, an unfamiliar juvenile rat was introduced (test
trial). To test long-term effects of the peptide, another social
recognition test was performed with the initial trial taking
place 73 h after administration of test compounds. Data are
expressed as a recognition ratio: RR = 𝑇2/(𝑇2 + 𝑇1), where
𝑇1 and 𝑇2 are the times spent on investigating the juvenile
animal during the initial and the test trial, respectively. An
RR not significantly different from 0.5 suggests that the test
animal has retained no memory of the introduced animal
between the two meetings, whereas an RR significantly lower
than 0.5 indicates that the test animal remembers the juvenile
animal when introduced to the animal for the second time.
3. Results
3.1. Epobis Stimulates Neurite Outgrowth fromMotor Neurons
In Vitro. To evaluate whether Epobis also has neuritogenic
effects in the peripheral nervous system, primary cultures of
rat motor neurons were exposed to the peptide in a range of
concentrations. Epobis induced a bell-shaped, concentration-
dependent stimulation of neurite outgrowth (𝑝 < 0.0001)
with maximal stimulation at 0.33𝜇M (Figure 1).
3.2. Epobis Reduces Release of TNF. Activation of microglia
and other macrophages leads to an increased secretion of
proinflammatory cytokines including TNF. Therefore, the
effects of EPO and Epobis on TNF secretion from AMJ2-C8
macrophages were detected indirectly from the survival of L-
cell in response to conditioned medium from the activated
macrophages.
A standard curve of L-cell viability relative to increasing
concentrations of recombinant TNF was plotted for each
individual experiment (Figure 2(a)). Conditioned medium
frommacrophage cultures treated with either EPO or Epobis
improved the survival of the L-cells, indicative of a decreased
TNF secretion from macrophages exposed to EPO and
Epobis (Figure 2(b)). L-cells exposed to conditionedmedium
from macrophages untreated with EPO or Epobis exhibited
viability of ∼48% relative to control. Treatment with 8.4 nM
EPO resulted in a significantly higher viability of ∼64%,
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Figure 1: Effects of Epobis on neurite outgrowth from motor neurons. (a) Representative fluorescence micrographs of rat motoneurons
grown for 24 h in the absence (top) or presence (bottom) of 0.33 𝜇M Epobis. Size bar: 10 𝜇m. (b) Neurite outgrowth in response to Epobis.
The graph showsmean and SEM from 3 independent experiments. Statistics was performed on nonnormalized data using a one-way ANOVA
for repeated measures (𝐹8,12 = 20.3, 𝑝 < 0.0001) followed by Tukey’s Multiple Comparison Test. ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001.
whereas the highest viability (∼68%) in response to treatment
with Epobis was obtained at a concentration of 2.7𝜇M (𝑝 <
0.05; Figure 2(b)).
To verify the observed effect of Epobis on cytokine
secretion in amore directmanner, TNF release wasmeasured
in primary cultures of rat microglia. First, the purity of
the cultures was estimated from fluorescence micrographs
of triple-stained cells, which demonstrated that 80% of the
cells in the cultures were microglia (Figure 2(c)). Microglia
stimulated with LPS for 24 h became activated and produced
soluble TNF. It was found that treatment with 0.9𝜇M, but not
8.1 𝜇M, Epobis caused a significant decrease in LPS-induced
TNF secretion from microglia cells (𝑝 < 0.05; Figure 2(d)).
3.3. Epobis Crosses the Blood-Brain Barrier. To test the dis-
tribution and dynamics of Epobis in response to systemic
administration, the concentrations of the peptide in blood
andCSFweremeasured in rats following a single s.c. injection
of biotinylated Epobis. The peptide was detectable already at
the time of the first blood sample (15min after administra-
tion) and remained detectable in the blood for at least 24 h.
However, the plasma concentration of Epobis peaked around
2 h after administration and decreased rapidly between 2 and
4 h after administration (Figure 3). In order to determine
whether Epobis is capable of crossing the BBB, cerebrospinal
fluid (CSF) samples were collected 2 h after a single s.c.
peptide administration. The obtained results revealed that
the peptide was present in the CSF at a concentration of
0.2 𝜇g/mL, which was approximately 20 times lower than the
plasma concentration at the same time point (Figure 3).
3.4. Epobis Has No Hematopoietic Activity. To test their
hematopoietic properties in vivo, EPO or Epobis was admin-
istered s.c. to mice twice per week over a period of 5 weeks,
and blood sampleswere collected once perweek. Administra-
tion of EPO caused statistically significant increases in both
hematocrit (Figures 4(a) and 4(b)) and hemoglobin levels
(Figure 4(c)). More than 1 week after the administration of
EPO had been terminated the hemoglobin levels, but not the
hematocrit levels, of EPO-treated mice were still significantly
different from the level prior to EPO administration. In
contrast, Epobis did not cause any statistically significant
increases in hematocrit or hemoglobin levels at any time
point investigated (Figures 4(a)–4(c), filled symbols).
3.5. Epobis Delays the Clinical Signs of Experimental Autoim-
mune Encephalomyelitis. To test the anti-inflammatory prop-
erties of Epobis in vivo, the peptide was administered to rats
undergoing EAE, an autoinflammatory animalmodel ofmul-
tiple sclerosis [40]. Animals undergoing EAE demonstrated
significant weight loss, but Epobis had no significant effects
on the weight changes or the survival of EAE animals when
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Figure 2: Effects of Epobis on TNF secretion. (a) Standard curve for the viability of cytokine-sensitive L-cell relative to the concentration of
recombinant TNF in the medium.The curve shows mean and SEM of 4 separate experiments. L-cell viability was evaluated using a one-way
ANOVA for repeated measures (𝐹5,18 = 14.96, 𝑝 < 0.0001) followed by Tukey’s Multiple Comparison Test (∗∗∗𝑝 < 0.001, when compared
to 0.00675 ng/mL TNF). (b) L-cell viability in response to exposure to conditioned medium from AMJ2-C8 macrophages. A value of 100%
corresponds to the viability of L-cells exposed to conditioned medium from unstimulated AMJ2-C8 cells. EPO was tested at a concentration
of 8.4 nM. Data from 4 separate experiments evaluated using one-way ANOVA for repeated measures (𝐹6,9 = 5.959, 𝑝 < 0.0160) followed by
Tukey’sMultiple Comparison Test. ∗𝑝 < 0.05when compared to 0𝜇MEpobis. (c) Representative fluorescencemicrograph of the ratmicroglia
cultures utilized for estimates of TNF secretion. The cells are double-stained with DAPI (for visualization of the total number of cells) and
an antibody against Iba-1/AIF-1 (for the visualization of microglia). Size bar: 10 𝜇m. (d) Estimate of TNF secretion from primary cultures of
rat microglia. The bars show mean and SEM from 3 separate experiments evaluated using Friedman’s test (𝑝 < 0.0278) followed by Dunn’s
Multiple Comparison Test. ∗𝑝 < 0.05, when compared to LPS-stimulated control untreated with Epobis.
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Figure 3: Dynamics of Epobis concentrations in plasma. Rats
received a single c.s. injection of Epobis (10mg/kg). Subsequently
blood samples were collected at 15min, 30min, 1 h, 2 h, 4 h, 8 h, and
24 h; CSF samples were collected only 1 h after administration. The
concentrations of Epobis in plasma and CSF (𝑛 = 6) were estimated
by ELISA.
compared to vehicle (see Additional File 1 in Supplementary
Material available online at http://dx.doi.org/10.1155/2016/
1346390). Immunohistochemical analysis demonstrated an
increased number of activated microglia in the brain stem
of EAE animals when compared to control, whereas no
difference could be observed between EAE animals receiving
Epobis or vehicle, respectively (see Additional File 2). How-
ever, Epobis appeared to delay the increase in the degree of the
clinical signs of EAE. In Figure 5, the clinical signs recorded
for the individual animals have been aligned according to
their first appearance. The clinical signs for Epobis-treated
animals increased less rapidly than for vehicle-treated ani-
mals, and at day 2 after onset of clinical signs, the clinical
signs for Epobis-treated animals were significantly lower than
those for vehicle-treated animals (𝑝 < 0.05). However, at
later time points, the clinical signs in Epobis-treated animals
were not significantly different from those of vehicle-treated
animals.
3.6. Epobis Improves Social Memory. The effects of Epobis
on short-term/working memory were tested using the social
recognition test on healthy adult rats. When performing
the social recognition test 1 h after administration of test
compounds, there was no significant difference between the
RRof animals treatedwith Epobis and vehicle, respectively (t-
test, 𝑝 > 0.05), and in both cases the RR was not significantly
different from 0.5 (t-test, 𝑝 > 0.05 for both control and
Epobis). However, when performing the social recognition
test 73 h after administration of test compounds, the RR of
Epobis-treated animals was significantly lower than that of
vehicle-treated animals (t-test, 𝑝 < 0.018) and significantly
different from0.5 (seeMaterials andMethods; t-test,𝑝 > 0.05
and 𝑝 < 0.0001 for control and Epobis, resp.; Figure 6).
4. Discussion
Here it is shown that Epobis can induce bell-shaped,
concentration-dependent stimulation of neurite outgrowth
in cultures of primary motoneurons. Moreover, Epobis has
anti-inflammatory effects in vitro as demonstrated by an abil-
ity to decrease TNF secretion from macrophages. Following
systemic administration the peptide is able to cross the BBB,
but in contrast to EPOno hematopoietic activity in vivo could
be demonstrated for the peptide. An analysis of the anti-
inflammatory effects of Epobis in vivo as evaluated using the
EAEmodel suggests that the peptide (10mg/kg, 1mL/kg, s.c.)
with 1 daily administration starting at day 10 after induction
of EAE can delay but not prevent the clinical signs of EAE.
Finally, a single administration of Epobis (10mg/kg, 1mL/kg,
s.c.) has long-term effects leading to an improved social
recognition memory 3 days after administration.
Epobis has previously been demonstrated to stimulate
neurite outgrowth in cultures of cerebellar granule neurons
and hippocampal neurons [29]. The data demonstrating also
an effect on the neurite outgrowth frommotoneurons suggest
that the peptide can act on neurons of both the peripheral
and central nervous system. However, a prerequisite for
Epobis to target neurons is an ability to penetrate the BBB.
Therefore, in vivo experiments with Epobis were initiated.
When administered systemically only a very small fraction
of recombinant EPO crosses the BBB [7]. Peptides generally
penetrate the BBB more readily than glycosylated proteins,
and therefore EPO-mimetic peptides could potentially enter
the CNS easier than recombinant EPO. Indeed, both the
peptides derived from the EPO:EPO receptor binding site 2,
Epotris [26] and Epobis, tested here, penetrate the BBB. The
plasma : CSF ratio for Epobis 2 h after administrationwas∼20
(Figure 3). This value is comparable to those from previous
studies with other peptides demonstrating ratios of ∼10–55
[32, 33, 36, 38].
EPO is known for its erythropoietic potential [1], a
function considered counterproductive for the neuropro-
tective potential of the protein [3]. Therefore, in addition
to potentially improved penetration of the BBB, the main
reason for designing EPO mimetics is to create compounds
that have the same neuroprotective properties as EPO but
not its erythropoietic properties. Although Epobis binds to
and signals through the EPO receptor the peptide could
not be demonstrated to have any erythropoietic properties
in mice when tested at the same administration schedule
utilized in other in vivo experiments (Figure 4). These data
are comparable to those obtainedwith Epotris, which at doses
between 10 and 40mg/kg was unable to promote significant
changes in hematocrit and hemoglobin levels [26].
The neuroprotective actions of EPO are known in part to
be a result of anti-inflammatory effects [3], including a reduc-
tion in the production of the proinflammatory cytokine TNF
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Figure 4: Effects of Epobis on hematopoiesis in vivo. Mice were injected with Epobis (𝑛 = 8), EPO (𝑛 = 10), or PBS (𝑛 = 6) twice per
week for 5 weeks (black arrowheads). Hematocrit (a, b) and hemoglobin levels (c) were estimated from blood samples taken once per week
for 6 weeks; first sample day, 0; last sample day, 42. Data are presented as actual values (a) and normalized to vehicle (PBS) from the same
day (100%, b and c). Statistics was performed on nonnormalized data using a one-way ANOVA for repeated measures followed by Tukey’s
Multiple Comparison Test. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001, Epobis versus vehicle.
[41–43]. For example, the protein can attenuate the immune
response triggered by CNS injury, partially by decreasing
TNF levels [44, 45]. Therefore, the anti-inflammatory poten-
tial of Epobis was investigated in vitro. As expected, exposure
to EPO caused a significant reduction in TNF secretion from
macrophages and also Epobis reduced TNF release from
macrophages, thus further demonstrating that the peptide
has an anti-inflammatory potential in vitro.
Subsequently, the effects of Epobis were evaluated in
vivo on the progression of EAE in rats. EAE is a classical
model for multiple sclerosis, and in addition to specific anti-
inflammatory effects, EPO and EPO derivatives are in this
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Figure 5: Effects of Epobis on the clinical signs of EAE. Following
induction of EAE the clinical signs were evaluated daily for all
animals. Only animals reaching a clinical score ≥1 before day 14
were included in the study. EAE was induced in 30 animals of which
20 developed clinical signs of EAE (10 receiving PBS; 10 receiving
Epobis). In the figure, the data have been aligned according to the
onset of clinical signs that were scored as follows: 0, no abnormality;
0.5, weak tail; 1, limp tail; 2, mild palsy of one or both hind legs; 3,
severe palsy of one or both hind legs; 4, complete paralysis of one or
both hind legs; 5, paralysis of one or both hind legs and beginning
paralysis of front legs; 6, moribund. Animals with a clinical score ≥4
were sacrificed immediately.The clinical scores of animals sacrificed
due to a clinical score ≥4 have been maintained at all subsequent
time points. Data are shown as mean and SEM. The data were
evaluated using a 2-way ANOVA for repeated measures followed
by a Bonferroni posttest. ∗𝑝 < 0.05 relative to the corresponding
control animals.
model believed to have beneficial effects due to antioxidative
and other neuroprotective actions [46, 47]. Epobis had only
minor effects on the progression of EAE. The peptide caused
no significant changes in the survival or the weight changes
of EAE animals, and the only detected significant change
observed in response to the peptide treatment was a slight
delay in the progression of the clinical signs (Figure 5).
The beneficial effects of Epobis on the progression of
EAE may be related to the reduced secretion of proinflam-
matory cytokines demonstrated in vitro. However, the exact
mechanisms of the anti-inflammatory effects of Epobis in
vivo would require additional studies preferentially using a
model demonstrating stronger effects in response to peptide
administration. An explanation for the weak effect of Epobis
on EAE might be found in the experimental setup. In a
study of the effects of EPO on MOG-induced EAE in mice,
EPO was administered 4 times between postimmunization
days 1 and 7. This treatment caused a reduction in the
clinical scores, a delay in the onset of the clinical signs,
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Figure 6: Effects of Epobis on social memory. Healthy adult rats
received a single administration of PBS (open columns, 𝑛 = 12) or
Epobis (solid columns, 𝑛 = 12), and social recognition tests were
initiated 1 h and 73 h later. Data are expressed as a recognition ratio:
RR = 𝑇2/(𝑇2 + 𝑇1), where 𝑇1 and 𝑇2 are the times spent on
investigating the juvenile animal during the initial and the test trial,
respectively. Data were evaluated using t-tests. ∗𝑝 < 0.05 relative to
the corresponding control animals.
and a lower incidence of EAE [48]. In another study, EPO
had the most pronounced effects on the clinical signs on
EAE in rats, when the protein was administered prior to
the onset of the clinical symptoms as compared to when
the animals already had clinical signs at the onset of EPO
administration [49]. Together, these observations suggest
that the effects of Epobis on the progression of EAE could
have been improved by administering the peptide earlier after
immunization. Moreover, the administered dose of Epobis
may be further optimized. It would be interesting to perform
additional studies of the effects of Epobis on EAE or other
neuroinflammatory models using a different administration
protocol andmore than one drug concentration.Moreover, if
Epobis has better in vivo effects on, for example, EAE using
a different administration protocol, it would be interesting to
relate the effects to changes in the activation of microglia and
other signs of inflammation.
Since EPO and EPO derivatives are known to have
beneficial effects on memory formation [4, 11, 13, 14, 16, 40,
50–52], it was evaluated whether Epobis also can improve
memory formation in healthy animals. Epobis was found to
improve the social recognition of healthy adult rats 3 days,
but not 1 h, after treatment (Figure 6), suggesting that Epobis-
induced changes in gene transcription and other downstream
effects lasting more than 1 h are required for the beneficial
effects on memory to appear or that the effects on memory
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peak several days after Epobis exposure.The result can also be
explained by the fact that Epobis needs time to cross BBB and
reach neuronal targets, since we have showed here that this
peptide peaks in plasma only 2 h after peripheral injections.
The mechanism for the Epobis-improved memory of healthy
animals is unclear, since most studies of the effects of EPO
and EPO derivatives on memory have been performed on
animals exposed to a brain injury or undergoing a disease
model. However, in a previous study of healthy young mice,
the beneficial effects onmemory of long-term EPO treatment
were found to be caused by effects on synaptic plasticity,
connectivity, and activity of hippocampal neuronal networks
[40] and a similar effect may explain the beneficial effects of
Epobis.
5. Conclusions
The synthetic, dendrimeric peptide, Epobis, derived from the
sequence of human EPO has previously been demonstrated
to be an EPO receptor agonist facilitating neuritogenesis
and neuronal survival in vitro [29]. Here it is shown that
it has anti-inflammatory effects in vitro as demonstrated
by an ability to decrease TNF secretion from AMJ2-C8
macrophages and rat primary microglia with an efficacy
comparable to, but with a lower potency, EPO. In vivo Epobis
is able to cross the BBB leading to a plasma : CSF ratio of
∼20, 2 h following systemic administration. Even after long-
term treatment, the peptide has no hematopoietic activity in
vivo. Acute treatment of EAE with a single daily injection of
Epobis delays but does not prevent the clinical signs of EAE.
Finally, Epobis has long-term but not short-term effects on
the social recognitionmemory of rats, leading to an improved
memory 3 days after administration. Thus, Epobis is a novel
EPO receptor agonist potentially suitable for the treatment of
neurodegenerative diseases.
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